Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric maltol oral suspension versus ferrous sulfate oral liquid in pediatric iron deficiency anemia
2018-000078-31Phase 3
- Sponsor
- Shield Therapeutics plc
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric maltol in iron deficiency anemia (IDA) (3 arms), sponsored by Shield Therapeutics plc. Primary endpoint: Safety and gastrointestinal tolerability.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2018-000078-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000078-31.